Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Expanded Results from a Dedicated Guideline-Directed Medical Therapy Clinic.

    Sep 28, 2025DOI: 10.1016/j.cardfail.2025.09.019Journal ArticleJCF

    Written by: Laura P CohenCharlotte PaquetteMichelle VassilopoulosAshley TringaleKathryn E SheppardChristine KoLana TsaoSafia ChaturClaire LinAferdita SpahillariYuxi LiuJames L Januzzi

    Find these authors on Roon

    AS
    Dr. Aferdita Spahillari
    Advanced Heart Failure · Duke University

    Summary

    BACKGROUND: Implementation of guideline directed medical therapy (GDMT) for heart failure (HF) care in general cardiology environments is suboptimal. A dedicated GDMT clinic was expanded to include individuals with HF across the full spectrum of left ventricular ejection fraction (LVEF).METHODS: Referred individuals were seen by advanced practice providers until maximally tolerated therapy was achieved. Achievement of optimal GDMT was evaluated and compared to patients from usual care matched in a 1:2 fashion. Key prognostic HF indicators were assessed.RESULTS: The mean (SD) age of 92 GDMT-eligible clinic participants was 66.5 (15.4) years, 25 (27.2%) were female;18 (19.6%) had LVEF ≥50%. From baseline to follow-up visit (12.9 weeks), the number of patients eligible for optimal GDMT with LVEF <50% increased from 12.0% to 91.3% (p<0.001); among eligible individuals with LVEF ≥50%, optimal GDMT increased from 5.6% to 77.8% (p=0.001). There was an increase in the proportion on optimal GDMT at ≥50% target dose (1.1% to 50.0%) and at target dose (0.0% to 30.4%). These changes were substantially greater than in the matched cohort of usual care patients. Among GDMT patients, significant improvements were observed in symptoms, NT-proBNP and important echocardiographic measurements. Kansas City Cardiomyopathy Questionnaire Overall and Clinical Summary Scores both significantly increased by 8 points (p=0.01) and 6-minute walk distance increased by 37 meters (p=0.03). GDMT administration was safe and well tolerated.CONCLUSIONS: Successful implementation of GDMT in a dedicated clinic embedded within a general cardiology practice was well-tolerated and effective to improve key outcomes across the entire spectrum of LVEF.
    ASDr. Aferdita Spahillari

    Dr. Aferdita Spahillari

    Cardiology · Advanced Heart Failure & Transplantation
    Duke University
    aferdita